Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Role of PARP Inhibitors in BRCA-Related Malignancies
AstraZeneca-Merck & Co.'s Lynparza wins Japanese nod for 3 cancer types | S&P Global Market Intelligence
Mechanism of targeting the interaction of EWS-FLI1 and PARP. EWS-FLI1... | Download Scientific Diagram
BRCA, HRR Deficiency, and PARP Inhibitors - ppt download
Mechanism of sensitivity to PARP inhibition in BRCA-deficient cells SSB | Download Scientific Diagram
PARP inhibitors in ovarian cancer - ScienceDirect
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression | Scientific Reports
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells - ScienceDirect
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Olaparib mechanism, specifically in BRCA-deficient cells compared to... | Download Scientific Diagram
PARP inhibitors in cancer treatment | OncologyPRO
PARP Inhibition: A New Approach To Cancer Therapy? Dr. Geert Kolvenbag - ppt download
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
Olaparib - Wikipedia
PARP Inhibitors: Where Are We in 2020 and What's Coming Next?
Olaparib - Wikipedia
藥學雜誌電子報145期
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
Cancers | Free Full-Text | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors | HTML
PARP inhibitor resistance: the underlying mechanisms and clinical implications | Molecular Cancer | Full Text
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance | Experimental & Molecular Medicine
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - National Cancer Institute
Lynparza recommended for approval in ovarian cancer | Cambridge Network
